Tofacitinib monotherapy and erectile dysfunction in rheumatoid arthritis: a pilot observational study.
Yusuf KarabulutHalise Hande GezerSelin Aktürk Esenİrfan EsenAli Riza TurkogluPublished in: Rheumatology international (2022)
We aimed to explore the effect of tofacitinib on erectile dysfunction (ED), as well as disease activity and health related quality of life in male patients with rheumatoid arthritis (RA). Forty eight male RA patients with ED were included. Demographic and clinical data at baseline and 6 month of treatment were recorded from patients' medical records. Disease activity was evaluated with the disease activity score on 28 joints (DAS28), quality of life with Health Assessment Questionnaire-Disability Index (HAQ-DI) and ED with International Index of Erectile Function-5 (IIEF-5). The patients were aged 45.58 [Formula: see text] 2.14 years with a disease duration of 79.33 [Formula: see text] 25.31 months. According to the IIEF-5, 17 (35.4%) patients had severe ED, 10 (20.8%) patients moderate ED, 10 (20.8%) patients mild to moderate ED and 11 (22.9%) patients mild ED. For the entire patient group, baseline median IIEF-5 score was significantly increased from 9.35 (5.30-19.40) to 9.90 (5.20-24.90), baseline median DAS28 was significantly decreased from 5.65 (4.80-6.70) to 5.00 (2.40-6.40), HAQ-DI from 1.70 (1.10-2.40) to 1.15 (0.40-2.20) at 6th month of treatment (all p value < 0.001). Also, quantitative change in IIEF-5 was significantly correlated with changes in DAS28 (r: - 0.735, p < 0.001) and HAQ-DI (r: - 0.700, p < 0.001). Tofacitinib monotherapy may improve ED severity and as well as disease activity and health related quality of life in male patients with RA complaining of ED.
Keyphrases
- disease activity
- rheumatoid arthritis
- end stage renal disease
- emergency department
- systemic lupus erythematosus
- ejection fraction
- newly diagnosed
- rheumatoid arthritis patients
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- clinical trial
- public health
- machine learning
- climate change
- risk assessment
- cross sectional
- cystic fibrosis
- staphylococcus aureus
- open label
- interstitial lung disease
- deep learning
- idiopathic pulmonary fibrosis
- data analysis
- psychometric properties
- double blind